DOI 10.1016/j.braindev.2026.104520
Outcomes of combination therapy with nusinersen, onasemnogene abeparvovec, and risdiplam over 3.5 years in a patient with prenatally diagnosed spinal muscular atrophy type 0: A case report.
Аннотация
BACKGROUND
Recently introduced disease-modifying therapies have markedly improved survival and motor outcomes, particularly when initiated presymptomatically or in the early symptomatic stage. However, reports on treatment of the most severe form, SMA type 0, remain extremely limited.
CASE REPORT: We report a patient with prenatally diagnosed spinal muscular atrophy type 0 who was treated with nusinersen and onasemnogene abeparvovec as early and as safely as possible, followed by risdiplam, for further motor acquisition. With continuous physiotherapy, the patient achieved independent walking at 2 years 11 months and showed sustained development without swallowing or respiratory difficulties up to 3.5 years of age.
DISCUSSION: Early intervention with combined use of disease-modifying therapies may be beneficial for patients with severe spinal muscular atrophy phenotypes. However, since evidence of efficacy and safety of combination therapy is still lacking, great caution should be paid to this treatment strategy, taking the patient's clinical status into account.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.